Evidence map›Paper›PMID 26916077›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2016

ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor.

Guang-Qian Xiao, Faqian Li, Pamela D Unger, Hani Katerji, Qi Yang, Loralee McMahon, David E Burstein

Open access · bronzeAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Guang-Qian XiaoDepartment of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
Faqian LiDepartment of Pathology, University of Minnesota, Twin Cities, MN, USA.
Pamela D UngerDepartment of Pathology, Lenox Hill Hospital-NS/LIJ Health System, New York, NY, USA.
Hani KaterjiDepartment of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
Qi YangDepartment of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
Loralee McMahonDepartment of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
David E BursteinDepartment of Pathology, Mount Sinai Medical Center, New York, NY, USA.
University of Rochester Medical Center · USLenox Hill Hospital · USMount Sinai Medical Center · USTwin Cities Orthopedics · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the function of zinc finger and BTB domain containing 16 (ZBTB16) in spermatogenesis is well documented, expression of ZBTB16 in germ cell tumors has not yet been studied. The aim of this study was to investigate the immunohistochemical expression and diagnostic utility of ZBTB16 in germ cell tumors. A total of 67 adult germ cell tumors were studied (62 testicular germ cell tumors, 2 ovarian yolk sac tumors, 1 mediastinal yolk sac tumor, and 2 retroperitoneal metastatic yolk sac tumors). The 62 testicular primary germ cell tumors are as follows: 34 pure germ cell tumors (20 seminomas, 8 embryonal carcinomas, 2 teratomas, 1 choriocarcinoma, 1 carcinoid, and 2 spermatocytic tumors) and 28 mixed germ cell tumors (composed of 13 embryonal carcinomas, 15 yolk sac tumors, 15 teratomas, 7 seminomas, and 3 choriocarcinomas in various combinations). Thirty-five cases contained germ cell neoplasia in situ. Yolk sac tumor was consistently reactive for ZBTB16. Among the 15 testicular yolk sac tumors in mixed germ cell tumors, all displayed moderate to diffuse ZBTB16 staining. ZBTB16 reactivity was present regardless of the histologic patterns of yolk sac tumor and ZBTB16 was able to pick up small foci of yolk sac tumor intermixed/embedded in other germ cell tumor subtype elements. Diffuse ZBTB16 immunoreactivity was also observed in 2/2 metastatic yolk sac tumors, 1/1 mediastinal yolk sac tumor, 2/2 ovarian yolk sac tumors, 2/2 spermatocytic tumors, 1/1 carcinoid, and the spermatogonial cells. All the other non-yolk sac germ cell tumors were nonreactive, including seminoma (n=27), embryonal carcinoma (n=21), teratoma (n=17), choriocarcinoma (n=4), and germ cell neoplasia in situ (n=35). The sensitivity and specificity of ZBTB16 in detecting yolk sac tumor among the germ cell tumors was 100% (20/20) and 96% (66/69), respectively. In conclusion, ZBTB16 is a highly sensitive and specific marker for yolk sac tumor.

Indexed as

Biomarkers, TumorEndodermal Sinus TumorFemaleHumansImmunohistochemistryMaleMediastinal NeoplasmsNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsPredictive Value of TestsPromyelocytic Leukemia Zinc Finger ProteinReproducibility of ResultsRetroperitoneal NeoplasmsTesticular NeoplasmsBiomarkers, TumorPromyelocytic Leukemia Zinc Finger ProteinZBTB16 protein, human

Identifiers

PMID26916077
OpenAlexW2276832021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.